Brii Biosciences receives breakthrough therapy designations for HBV treatments
Brii Biosciences Limited, a biotechnology company developing therapies for diseases with high unmet need, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for BRII-877 (tobevibart) and BRII-835 (elebsiran). These investigational therapies target the hepatitis B virus (HBV) and are part of Brii Bio’s […]